[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100330050":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":17,"responsibleParty":32,"collaborators":36,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":7,"enrollmentInfo":66,"targetDuration":69,"studyType":70,"phases":7,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Academisch Ziekenhuis Maastricht","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Vivianne CG Tjan-Heijnen, MD, PhD","CONTACT","+31 (0) 43 3877025","vcg.tjan.heijnen@mumc.nl",{"name":15,"role":11,"phone":12,"phoneExt":7,"email":16},"Sandra ME Geurts, PhD","sandra.geurts@mumc.nl",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":7,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Multiple hospitals in the Netherlands (see Eligibility)","RECRUITING","Maastricht","Netherlands","NL",{"type":25,"coordinates":26},"Point",[27,28],5.68889,50.84833,{"lat":28,"lon":27},[31],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","V.C.G. Tjan-Heijnen","Professor of medical oncology",[37,40,42,44,46,48,50,52,54],{"name":38,"class":39},"Novartis","INDUSTRY",{"name":41,"class":39},"Pfizer",{"name":43,"class":39},"Roche Pharma AG",{"name":45,"class":39},"Eli Lilly and Company",{"name":47,"class":6},"ZonMw: The Netherlands Organisation for Health Research and Development",{"name":49,"class":39},"Eisai Inc.",{"name":51,"class":39},"Daiichi Sankyo",{"name":53,"class":39},"AstraZeneca",{"name":55,"class":39},"Gilead Sciences","100330050","southeast-netherlands-advanced-metastatic-breast-cancer-registry-100330050",false,"NCT03577197","Southeast Netherlands Advanced Metastatic Breast Cancer Registry","Southeast Netherlands Advanced Breast Cancer Registry","SONABRE","Inclusion Criteria:\n\n* Diagnosed with de novo or recurrent advanced breast cancer since 2007\n* Diagnosed with or treated for advanced breast cancer in one of the participating hospitals\n* Participating hospitals (period of inclusion): Maastricht UMC+ (2007-2025), Zuyderland hospitals Sittard\u002FHeerlen (2007-2025), Amphia Hospital Breda (2013-2025), Catharina Hospital Eindhoven (2007-2025), Elkerliek Hospital Helmond (2010-2025), Maxima Medical Center Veldhoven\u002FEindhoven (2007-2025), Jeroen Bosch Hospital Den Bosch (2013-2025), Laurentius Hospital Roermond (2007-2025), St. Annaziekenhuis Geldrop (2007-2025), St. Elisabeth Hospital Tilburg (2007-2009), St. Jans Gasthuis Weert (2007-2025), VieCuri Medical Center Venlo\u002FVenray (2013-2025), all in the Netherlands.\n* Hospitals (and periods) were eligible for inclusion if (distant) registration from Maastricht UMC+ was possible.\n* The inclusion period may be prolonged after 2025.\n\nExclusion Criteria: none","ALL","18 Years",{"count":67,"type":68},7000,"ESTIMATED","5 Years","OBSERVATIONAL","The Southeast Netherlands Advanced Breast Cancer (SONABRE) Registry is a real life multi-center study. The registry aims to include all patients diagnosed with advanced breast cancer as of 2007 in 11 hospitals in the Netherlands. Data on patient, tumor and treatment characteristics are collected retrospectively from electronic medical files by trained registry clerks.",[73,74],"Advanced Breast Cancer","Metastatic Breast Cancer",[76,77,78],"Breast neoplasms","Neoplasm Metastasis","Registry","2024-07-19",{"date":81,"type":82},"2024-07-23","ACTUAL",{"date":84,"type":82},"2007-01-01",{"date":86,"type":68},"2027-12-31",{"name":5,"class":6},1]